Laurus Labs Limited a pharmaceutical and biotechnology company, which develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations.
Products and Services
Active Pharmaceutical Ingredients (APIs)
The c…
Analysis
Hope premium
Laurus Labs Limited is priced well ahead of what the underlying numbers justify, a pattern we describe as a hope premium.
On valuation, the picture is expensive. The owner-earnings multiple stands at 230.9×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 40% a year, against analyst forecasts of 53%. The price, in other words, assumes less than the experts do.
Growth is solid; the safety picture is adequate. The company scores 20/20 on our value-creation score: strong value creator.
No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.
360° rank · history
1007550250
Jan 202325
10
2023202420252026
All-time high
31
Jan 2025
All-time low
1
Jan 2024
Average rank
15
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
5
46
55
52
Price/Earnings
1
5
15
63
Price/Book
3
28
49
37
Dividend Yield
31
12
15
28
Value (overall)
4
15
27
47
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.